Michael D. Jain

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

Michael D. Jain

Apr 11, 2025, 15:47 | Blog

Major microbiome disruption and Toxicities Following Idecabtagene Vicleucel in Multiple Myeloma patients

Muzaffar Qazilbash, Professor of Medicine at UT- MD Anderson Cancer Center, shared a post on…

Mar 4, 2025, 04:35 | Blog

Razan Mohty: Outcomes of anti-CD19 CART for lymphoma in octogenarians

Razan Mohty, Assistant Professor at UAB Medicine, shared a paper she and her colleagues authored…

Aug 5, 2024, 00:11 | Insight

5 year outcomes of SOC Axicabtagene Ciloleucel

Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre,…

Aug 4, 2024, 09:41 | Insight

Michael Jain: 5-year outcomes of standard-of-care Axicabtagene Ciloleucel in lymphoma patients

Michael Jain, Oncologist at Moffitt Cancer Center, shared on X: "What is important for long-term…

All: 4 Posts: 1 - 100

'

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology

'

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025

'

USA vs Europe: Who Does Cancer Screening Better?

'

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

'

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023